I'ROM GROUP

INFORMATION

2020.8.6: Summary of Business Results for the First Quarter Ended June 30, 2020[Japan GAAP] (Consolidated)
2020.5.12: Summary of Business Results for the Fiscal Year Ended March 31, 2020 [Japan GAAP] (Consolidated)
2020.2.6: Summary of Business Results for the Third Quarter Ended December 31, 2019 [Japan GAAP] (Consolidated)
2019.11.7: Summary of Business Results for the Second Quarter Ended September 30, 2019[Japan GAAP] (Consolidated)
2019.8.8: Summary of Business Results for the First Quarter Ended June 30, 2019[Japan GAAP] (Consolidated)
2019.5.10: Summary of Business Results for the Fiscal Year Ended March 31, 2019 [Japan GAAP] (Consolidated)
2019.2.26: I’rom Group announces the resolution regarding share repurchase.
2019.2.7: Summary of Business Results for the Third Quarter Ended December 31, 2018 [Japan GAAP] (Consolidated)
2018.12.14: Initiating an SMO business in Australia through partnership with South Australian GP Partners.
2018.11.8: Summary of Business Results for the Second Quarter Ended September 30, 2018 [Japan GAAP] (Consolidated)

2019.2.26: I’rom Group announces the resolution regarding share repurchase.
2018.11.8: I’rom Group announces interim dividends from surplus, with a record date of September 30, 2018.
2018.11.8: I’rom Group announces the resolution regarding share repurchase.
2018.1.29: Establishment of a Subsidiary in Hong Kong
2017.11.9: I’rom Group announces interim dividends from surplus, with a record date of September 30, 2017.
2017.10.17: I’rom Group concludes a partnership agreement with OKEIOS, a subsidiary of OKWAVE.
2017.8.23: IDT Australia announces the completion of the CMAX transaction.
2017.8.23: I’rom Group completes acquisition of all the shares in CMAX.
2017.3.31: I’rom Group concludes a share exchange agreement with Ethic Co., Ltd.
2017.1.16: UPDATE: From Management

2018.12.14: Initiating an SMO business in Australia through partnership with South Australian GP Partners.
2018.10.30: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Censo Biotechnologies.
2018.10.5: CMAX win Business SA 2018 Export Awards.
2018.9.13: Boehringer Ingelheim, UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce conclusion of a collaborative research and development deal to develop a gene therapy for cystic fibrosis based on the vector technology developed by ID Pharma, I’rom Group subsidiary.
2018.8.22: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Elpis Biomed.
2018.8.21: I’rom Group concludes a strategic partnership agreement with Beroni Group.
2018.6.22: ID Pharma granted EU patent for the technology regarding production of functional classical brown adipocytes from human pluripotent stem cells.
2018.5.28: I’rom Group concludes a strategic partnership agreement with Japanese Bio company Dendrix.
2018.2.2: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based QurAlis Corporation.
2018.1.9: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based Q-State Biosciences, Inc..

2020.8.6: Summary of Business Results for the First Quarter Ended June 30, 2020[Japan GAAP] (Consolidated)
2020.5.12: Summary of Business Results for the Fiscal Year Ended March 31, 2020 [Japan GAAP] (Consolidated)
2020.2.6: Summary of Business Results for the Third Quarter Ended December 31, 2019 [Japan GAAP] (Consolidated)
2019.11.7: Summary of Business Results for the Second Quarter Ended September 30, 2019[Japan GAAP] (Consolidated)
2019.8.8: Summary of Business Results for the First Quarter Ended June 30, 2019[Japan GAAP] (Consolidated)
2019.5.10: Summary of Business Results for the Fiscal Year Ended March 31, 2019 [Japan GAAP] (Consolidated)
2019.2.7: Summary of Business Results for the Third Quarter Ended December 31, 2018 [Japan GAAP] (Consolidated)
2018.11.8: Summary of Business Results for the Second Quarter Ended September 30, 2018 [Japan GAAP] (Consolidated)
2018.5.11: Summary of Business Results for the Fiscal Year Ended March 31, 2018 [Japan GAAP] (Consolidated)
2018.2.8: Summary of Business Results for the Third Quarter Ended December 31, 2017 [Japan GAAP] (Consolidated)